Literature DB >> 17545699

Immune responses to abacavir in antigen-presenting cells from hypersensitive patients.

Annalise M Martin1, Coral-Ann Almeida, Paul Cameron, Anthony W Purcell, David Nolan, Ian James, James McCluskey, Elizabeth Phillips, Alan Landay, Simon Mallal.   

Abstract

OBJECTIVES: A potentially life-threatening hypersensitive reaction accompanies the use of HIV nucleoside analogue abacavir (ABC) in 4-8% of Caucasian individuals. HLA-B*5701 and Hsp70 493T alleles have been shown to predict susceptibility to this hypersensitivity. DESIGN AND METHODS: This study was undertaken to provide a mechanistic understanding of the highly significant genetic association of HLA Class I and Hsp70 alleles with ABC hypersensitivity.
RESULTS: In this study an ABC-induced localization of intracellular HSP70 to endosomal vesicles of antigen-presenting cells was demonstrated. This ABC-stimulated redistribution of endogenous HSP70 was substantially higher in the genetically homogenous HLA-B*5701, Hsp70 493T ABC-hypersensitive individuals and ABC-naive individuals in comparison with the heterogeneous tolerant patients (P = 0.023). Increased expression of HSP70 was also detected in the hypersensitive group as measured by flow cytometry (P = 0.032). Blocking of HSP70 and HSP70 cell surface receptors CD14 and TLR2 abrogated ABC-stimulated HSP70 redistribution in sensitized individuals to basal levels (P < 0.004). In addition, the use of TcRalphabeta and HLA-B57/58 antibodies also ablated the expression of HSP70. Cells expressing the activation markers CD40 were increased after ABC stimulation in the hypersensitive patients (P = 0.006). ABC-stimulated interferon-gamma levels were higher in hypersensitive patients in comparison with ABC-tolerant individuals with a mean of 123.54 versus 0 pg/ml (P = 0.001).
CONCLUSION: The present data indicates that ABC stimulates an innate immune response and activates antigen-presenting cells via the endogenous HSP70-mediated Toll-like receptor pathway in genetically susceptible individuals potentially initiating the immuno-pathological hypersensitive response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17545699     DOI: 10.1097/QAD.0b013e3280119579

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  18 in total

1.  Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire.

Authors:  David A Ostrov; Barry J Grant; Yuri A Pompeu; John Sidney; Mikkel Harndahl; Scott Southwood; Carla Oseroff; Shun Lu; Jean Jakoncic; Cesar Augusto F de Oliveira; Lun Yang; Hu Mei; Leming Shi; Jeffrey Shabanowitz; A Michelle English; Amanda Wriston; Andrew Lucas; Elizabeth Phillips; Simon Mallal; Howard M Grey; Alessandro Sette; Donald F Hunt; Soren Buus; Bjoern Peters
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

Review 2.  Delayed drug hypersensitivity: models of T-cell stimulation.

Authors:  Jacqueline Adam; Werner J Pichler; Daniel Yerly
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

Review 3.  Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing.

Authors:  M A Martin; T E Klein; B J Dong; M Pirmohamed; D W Haas; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2012-02-29       Impact factor: 6.875

Review 4.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

5.  Transcriptome analysis of monocyte-HIV interactions.

Authors:  Rafael Van den Bergh; Eric Florence; Erika Vlieghe; Tom Boonefaes; Johan Grooten; Erica Houthuys; Huyen Thi Thanh Tran; Youssef Gali; Patrick De Baetselier; Guido Vanham; Geert Raes
Journal:  Retrovirology       Date:  2010-06-14       Impact factor: 4.602

6.  Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism.

Authors:  Ayman Elsheikh; Sidonie N Lavergne; J Luis Castrejon; John Farrell; Haiyi Wang; Jean Sathish; Werner J Pichler; B Kevin Park; Dean J Naisbitt
Journal:  J Immunol       Date:  2010-10-27       Impact factor: 5.422

7.  A transgenic mouse model for HLA-B*57:01-linked abacavir drug tolerance and reactivity.

Authors:  Marco Cardone; Karla Garcia; Mulualem E Tilahun; Lisa F Boyd; Sintayehu Gebreyohannes; Masahide Yano; Gregory Roderiquez; Adovi D Akue; Leslie Juengst; Elliot Mattson; Suryatheja Ananthula; Kannan Natarajan; Montserrat Puig; David H Margulies; Michael A Norcross
Journal:  J Clin Invest       Date:  2018-05-21       Impact factor: 14.808

8.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

Review 9.  Successful translation of pharmacogenetics into the clinic: the abacavir example.

Authors:  Elizabeth Phillips; Simon Mallal
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

10.  PharmGKB summary: abacavir pathway.

Authors:  Julia M Barbarino; Deanna L Kroetz; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-05       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.